1. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials∗ 
A.Michael Lincoff, MD, LeRoy A LeNarz, MD, George J Despotis, MD, Peter K Smith, MD, Joan E Booth, RN, Russell E Raymond, Shelly K Sapp, MS, Catherine F Cabot, MD, James E Tcheng, MD, Robert M Califf, MD, Mark B Effron, MD, Eric J Topol, MD 
The Annals of Thoracic Surgery 
Volume 70, Issue 2, Pages (August 2000)
DOI: /S (00)

2. Fig 1
Histogram chart of timing of initiation of coronary artery bypass grafting operation relative to discontinuation of abciximab administration.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

3. Fig 2
Box-and-whisker plot of the volume of perioperative mediastinal- and chest-tube drainage in the placebo and abciximab groups. The box spans the interquartile range (25th to 75th percentiles), whereas the line within the box denotes the median. Whiskers extend from the 10th to the 90th percentiles. The diamond symbol represents the mean.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

4. Fig 3
Number of transfused packed red blood cell or whole blood units in the placebo and abciximab groups.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )

5. Fig 4
Box-and-whisker plot of the maximum decrease in hemoglobin levels, adjusted for transfusion [14], in the placebo and abciximab groups. See Figure 2 for explanation of box-and-whisker plot.
The Annals of Thoracic Surgery  , DOI: ( /S (00) )